scholarly journals Does a routine post brush bronchial wash increase the yield in diagnosis of lung cancer?

2017 ◽  
Vol 5 (7) ◽  
pp. 2878 ◽  
Author(s):  
Mathan Raj S. ◽  
Sowmiya Murali
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fiberoptic Bronchoscopy ◽  
Small Cell ◽  
Fibreoptic Bronchoscopy ◽  
Small Cell Lung ◽  
Brush Cytology ◽  
Tissue Samples ◽  
Bronchial Wash

Background: Lung cancer is the most common cause of cancer-related death in both men and women. 80% of the lung cancers are non-small cell lung cancer (NSCLC) and 20% are small cell lung cancer (SCLC). Flexible fiberoptic bronchoscopy is commonly used for diagnostic and staging purposes. Endoscopically visible abnormalities are approached with traditional biopsy forceps, brushings, and washings. Objectives were to assess the yield of bronchial washings, brush cytology and to compare the yield of pre and post brush bronchial washings.Methods: Patients with suspicion of lung cancer will be subjected to bronchoscopy using flexible fibreoptic bronchoscopy. Multiple procedures performed for the retrieval of tissue samples will include bronchial washings (pre and post brushing), bronchial brushing and endobronchial biopsy.Results: A total of 57 cases were included in the study with 40 (70.2%) males and 17 females (29.8%). The yield of pre-brush bronchial washings, post brush bronchial washings and bronchial brushings were 31.6% (18 of 57), 31.6% (18 of 57) and 61.4% (35 of 57) respectively. Biopsy was positive for malignancy in 11 of 19 (58.2%) cases. Adenocarcinoma was the commonest type seen in 32 (56.1%) patients. Of the 27 cases with endobronchial growth 11 were adenocarcinoma (40.7%).Conclusions: There was no difference between the yield of pre-brush washing and post brush washing. The yield of brush cytology was significantly more than the yield of bronchial washings. There is an increase in the yield after adding both pre and post brush bronchial wash. 

scholarly journals miR-196b-5p–mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer

2020 ◽  
Vol 117 (8) ◽  
pp. 4347-4357 ◽  
Author(s):  
Guang Liang ◽  
Wei Meng ◽  
Xiangjie Huang ◽  
Wangyu Zhu ◽  
Changtian Yin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rna Binding ◽  
Nsclc Patient ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tissue Samples ◽  
Underlying Mechanisms

Lung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases. The RNA binding protein, QKI, belongs to the STAR family and plays tumor-suppressive functions in NSCLC. QKI-5 is a major isoform of QKIs and is predominantly expressed in NSCLC. However, the underlying mechanisms of QKI-5 in NSCLC progression remain unclear. We found that QKI-5 regulated microRNA (miRNA), miR-196b-5p, and its expression was significantly up-regulated in NSCLC tissues. Up-regulated miR-196b-5p promotes lung cancer cell migration, proliferation, and cell cycle through directly targeting the tumor suppressors, GATA6 and TSPAN12. Both GATA6 and TSPAN12 expressions were down-regulated in NSCLC patient tissue samples and were negatively correlated with miR-196b-5p expression. Mouse xenograft models demonstrated that miR-196b-5p functions as a potent onco-miRNA, whereas TSPAN12 functions as a tumor suppressor in NSCLC in vivo. QKI-5 bound to miR-196b-5p and influenced its stability, resulting in up-regulated miR-196b-5p expression in NSCLC. Further analysis showed that hypomethylation in the promoter region enhanced miR-196b-5p expression in NSCLC. Our findings indicate that QKI-5 may exhibit novel anticancer mechanisms by regulating miRNA in NSCLC, and targeting the QKI5∼miR-196b-5p∼GATA6/TSPAN12 pathway may enable effectively treating some NSCLCs.

scholarly journals Pathological analysis of hesperetin-derived small cell lung cancer by artificial intelligence technology under fiberoptic bronchoscopy

2021 ◽  
Vol 18 (6) ◽  
pp. 8538-8558
Author(s):  
Xiaoli Zhang ◽  
◽  
Ziying Yu ◽  
Keyword(s):  
Artificial Intelligence ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Cell Lung Cancer ◽  
Fiberoptic Bronchoscopy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Artificial Intelligence Technology

<abstract> <p>Lung cancer is one of the most common tumors. There are 1.8 million new cases worldwide each year, accounting for about 13% of all new tumors. Lung cancer is the most important cause of cancer-related deaths. 1.4 million people die of lung cancer each year. This article uses artificial intelligence technology to analyze the pathology of hesperetin-derived small cell lung cancer under fiberoptic bronchoscopy. This article takes 48 lung slice samples as the research object. Among them, 36 cases of lung small cell carcinoma have history slices from Lhasa City Institute of Biology, the patient has complete cases, and the other 12 normal lung slices come from Xinjiang Biotechnology Laboratory. In this paper, the above-mentioned 36 lung cancer slices became the study group, and 12 normal slices became the reference group. This article presents a method for hesperetin-fiber bronchoscope to study the pathological mechanism of lung small cell carcinoma (H-FBS), which is used to study slices. The above-mentioned 48 samples were taken for slice observation. First, the 48 slices were technically tested by artificial intelligence fiber bronchoscope combined with hesperetin derivatives, and then the slice observation results were verified by CTC technology. In addition, in each step, the C5orf34 in the tissue is detected separately, which is beneficial to adjust the content of C5orf34 so that the treatment of lung cancer can control the development of lung cancer under fiberoptic bronchoscopy. Experimental results show that the diagnostic accuracy rate of this method is 97.9%, which is higher than that of lung biopsy (89%); compared with multiple CTC detection, the cost is low and the time is shor.</p> </abstract>

scholarly journals MLPA-analysis of TP53 gene in patients with small-cell lung cancer

2020 ◽  
pp. 83-85
Author(s):  
Г.Ф. Гималова ◽  
З.С. Абдуллин ◽  
Э.К. Хуснутдинова
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Structural Changes ◽  
Malignant Tumors ◽  
Tp53 Gene ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tissue Samples ◽  
The Republic

Мелкоклеточный рак легкого (МРЛ) составляет около 15-20% всех случаев РЛ и относится к наиболее злокачественно текущим опухолям. В более чем 90 % случаев МРЛ выявляются мутации гена TP53. Целью нашего исследования являлся анализ структурных изменений хромосомной области 17p13 у больных МРЛ из Республики Башкортостан. Материалом исследования служили 70 образцов тканей легких больных МРЛ. Методом исследования являлся MLPA-анализ. Делеции и/или дупликации в кодирующих областях гена TP53 выявлены в 40% образцов, в т.ч. дупликации первого (23% образцов) и делеции 4-6-го и 11-го экзонов гена TP53 (17% образцов). Кроме того, в четырех образцах выявлена мутация c.1100delC гена CHEK2. Small cell lung cancer (SCLC) accounts for about 15-20% of all lung cancer cases and is one of the most malignant tumors. In more than 90% of cases of SCLC, mutations of the TP53 gene are detected. The aim of our study was to analyze the structural changes in the 17p13 chromosomal region in patients with SCLC from the Republic of Bashkortostan. We used 70 lung tissue samples from patients with SCLC. The study was conducted using MLPA. Deletions and/or duplications in the coding regions of the TP53 gene were detected in 40% of the samples, including duplications of the first exon (23% of the samples) and deletions of the 4-6th and 11th exons of the TP53 gene (17% of the samples). Besides, the CHEK2 c.1100delC mutation was detected in four samples.

scholarly journals Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

2016 ◽  
Vol 140 (11) ◽  
pp. 1259-1266 ◽  
Author(s):  
Marisa Dolled-Filhart ◽  
Darren Locke ◽  
Tiffany Murphy ◽  
Frank Lynch ◽  
Jennifer H. Yearley ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Stroma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Scoring Method ◽  
Tissue Samples ◽  
Tumor Bank ◽  
Programmed Death

Context.— With the abundance of therapeutics targeted against programmed death receptor-1 and its ligand (PD-L1) that are currently approved or in clinical development, there is interest in identifying those patients most likely to respond to these drugs. Expression of PD-L1 may be an indicator of an initial and robust inflammatory response to the presence of tumor cells. Therefore, tumors that express PD-L1 may be the most likely to respond to therapies that interrupt the negative feedback mechanism that leads to PD-L1 upregulation. Objective.— To develop a prototype immunohistochemistry assay using the anti–PD-L1 antibody clone 22C3. Design.— The assay was developed and optimized using commercially available reagents and archival tumor-bank tissue. Results.— The optimized immunohistochemistry method had high precision and reproducibility. Using the prototype assay in 142 non–small cell lung cancer and 79 melanoma archival tumor-bank tissue samples, PD-L1 staining was observed at the plasma membrane of nucleated tumor and nontumor cells and, in some cases, as a distinct lichenoid pattern at the tumor-stroma border. Using a preliminary scoring method, 56% (80 of 142) of non–small cell lung cancer and 53% (42 of 79) of melanoma samples were defined as PD-L1+ based on a modified H-score of 1 or more or the presence of a distinctive staining pattern at the tumor-stroma interface. Conclusions.— The immunohistochemistry assay using the anti–PD-L1 antibody 22C3 merits further investigation in clinical trials and prevalence assessments to further understand the prognostic and predictive value of PD-L1 expression in cancer.

Small-Cell Lung Cancer: Importance of Fiberoptic Bronchoscopy in the Evaluation of Complete Remission

1989 ◽  
Vol 75 (3) ◽  
pp. 266-268 ◽  
Author(s):  
Maurizio Tondini ◽  
Adriano Rizzi
Keyword(s):  
Lung Cancer ◽  
Complete Remission ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fiberoptic Bronchoscopy ◽  
Small Cell ◽  
Small Cell Lung ◽  
X Ray ◽  
Chest X Ray

The authors report their eight-year experience on the methodical of fiberbronchoscopy in the evaluation of complete remission in 140 patients affected by small-cell lung cancer. The higher reliability of fiberbronchoscopy than of standard chest X-ray is emphasized.

Amyloid-like fibrils are not detected in non-small cell lung cancer tissue samples

2011 ◽  
Vol 29 (2) ◽  
pp. 614-617
Author(s):  
Luiz Henrique de Lima Araújo ◽  
Luciana W. Pinto ◽  
Luciene F. Schluckebier ◽  
Joyce L. de Moraes ◽  
Paulo A. Faria ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cancer Tissue ◽  
Lung Cancer Tissue ◽  
Small Cell Lung ◽  
Tissue Samples

scholarly journals Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Milena Pązik ◽  
Katarzyna Michalska ◽  
Marta Żebrowska-Nawrocka ◽  
Izabela Zawadzka ◽  
Mariusz Łochowski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tissue Samples ◽  
Blood Samples ◽  
Expression Levels ◽  
Genes Expression

Abstract Background The RAS family protooncogenes, including KRAS, NRAS and HRAS, encode proteins responsible for the regulation of growth, differentiation and survival of many cell types. The HRAS and KRAS oncogene mutations are well defined, however, the clinical significance of RAS expressions in non–small-cell lung cancer (NSCLC) is still uncertain. Methods A total of 39 whole blood samples of NSCLC (the investigated group), collected at three points of time: at the time of diagnosis, 100 days and 1 year after the surgery as well as 35 tissue samples obtained during the surgery were included in this study. HRAS and KRAS genes mRNA expression were assessed using quantitative real-time polymerase chain reaction techniques. Results Increased relative HRAS mRNA level in blood was found significantly more frequently in the group of smokers (p = 0.008). Patients with squamous cell carcinoma subtypes of NSCLC were more likely to show an overexpression of HRAS gene in blood, but not statistically significant (p = 0.065). In tumor tissue overexpression of HRAS gene was associated with adenocarcinoma subtype (p = 0.049). No statistically significant associations were found for the expression of KRAS with any clinicopathological parameters, except the age of patients, within the study. There were no differences between the relative HRAS and KRAS genes expression levels in blood samples taken from the same patients during the 3 observation points, as well as between blood collected from patients before surgery and tissue samples obtained during operation. Conclusion The potential associations between high HRAS expression levels, age, smoking status and histological type of cancer were observed, which emphasizes the need for further study of the RAS family. Therefore, subsequent research involving larger numbers of patients and a longer follow-up, as well as multicenter study are necessary to confirm our findings.

Sign in / Sign up

Export Citation Format

Share Document